Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jun;102(6):968-971.
doi: 10.3324/haematol.2017.165605.

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification

Lesley-Ann Sutton  1   2 , Anastasia Hadzidimitriou  3 , Panagiotis Baliakas  1 , Andreas Agathangelidis  4 , Anton W Langerak  5 , Stephan Stilgenbauer  6 , Sarka Pospisilova  7 , Zadie Davis  8 , Francesco Forconi  9 , Frederic Davi  10 , Paolo Ghia  11 , Richard Rosenquist  1   2 , Kostas Stamatopoulos  1   3 ; European Research Initiative on CLL (ERIC)
Affiliations
Editorial

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification

Lesley-Ann Sutton et al. Haematologica. 2017 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Historical timeline of immunogenetic studies in chronic lymphocytic leukemia (CLL). IG: immunoglobulin; BcR: B cell receptor; SHM: somatic hypermutation; PFS: progression-free survival; M-CLL: mutated CLL; U-CLL: unmutated CLL; FCR: fludarabine, cyclophosphamide and rituximab; OR: overall response.
Figure 2.
Figure 2.
Kaplan-Meier curves for overall survival (OS) and time-to-first-treatment (TTFT) in CLL patients carrying del(17p). M-CLL harboring del(17p) exhibit significantly longer OS (A) and TTFT (B) compared to U-CLL carrying the same genetic defect. Cases included in this analysis are part of a multi-institutional cohort from our collaborative consortium comprising 8563 CLL patients. TTFT analysis was performed in early stage (Binet A) patients. M-CLL: mutated CLL; U-CLL: unmutated CLL.
See this image and copyright information in PMC

References

    1. Vardi A, Agathangelidis A, Sutton LA, Ghia P, Rosenquist R, Stamatopoulos K. Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. Cancer Res. 2014;74(16):4211–4216. - PubMed
    1. Wiestner A. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology Am Soc Hematol Educ Program. 2014;2014(1):125–134. - PubMed
    1. Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22–35. - PubMed
    1. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102(8):1515–1525. - PMC - PubMed
    1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847. - PubMed

Publication types

MeSH terms